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Background: Sepp1 transports selenium, but its complete role in selenium homeostasis is not known.
Results: Deletion of Sepp1 in hepatocytes increases liver selenium at the expense of other tissues and decreases whole-body
selenium by increasing excretion.
Conclusion: Sepp1 production by hepatocytes retains selenium in the organism and distributes it from the liver to peripheral
tissues.
Significance: Sepp1 is central to selenium homeostasis.
Sepp1 is a widely expressed extracellular protein that in
humans andmice contains 10 selenocysteine residues in its pri-
mary structure. Extra-hepatic tissues take up plasma Sepp1 for
its selenium via apolipoprotein E receptor-2 (apoER2)-medi-
ated endocytosis. The role of Sepp1 in the transport of selenium
from liver, a rich source of the element, to peripheral tissues was
studied using mice with selective deletion of Sepp1 in hepato-
cytes (Sepp1c/c/alb-cre/ mice). Deletion of Sepp1 in hepato-
cytes lowered plasma Sepp1 concentration to 10% of that in
Sepp1c/c mice (controls) and increased urinary selenium excre-
tion, decreasing whole-body and tissue selenium concentrations.
Under selenium-deficient conditions, Sepp1c/c/alb-cre/ mice
accumulated selenium in the liver at the expense of extra-he-
patic tissues, severely worsening clinical manifestations of die-
tary selenium deficiency. These findings are consistent with
there being competition for metabolically available hepatocyte
selenium between the synthesis of selenoproteins and the syn-
thesis of selenium excretory metabolites. In addition, selenium
deficiency down-regulated the mRNA of the most abundant
hepatic selenoprotein, glutathione peroxidase-1 (Gpx1), to 15%
of the selenium-replete value, while reducing Sepp1mRNA, the
most abundant hepatic selenoprotein mRNA, only to 61%. This
strongly suggests that Sepp1 synthesis is favored in the liver over
Gpx1 synthesis when selenium supply is limited, directing hep-
atocyte selenium to peripheral tissues in selenium deficiency.
We conclude that production of Sepp1 by hepatocytes is central
to selenium homeostasis in the organism because it promotes
retention of selenium in the body and effects selenium distribu-
tion fromthe liver to extra-hepatic tissues, especially under sele-
nium-deficient conditions.
Selenium is an essential micronutrient that functions
through selenoproteins (1). Some tissues, e.g. testis, kidney, and
bone marrow, synthesize selenoproteins for export and there-
fore have greater requirements for selenium than other tissues.
The brain must have a reliable supply of selenium for its
viability.
Because dietary selenium intake varies widely, physiological
mechanismsmust regulate whole-body selenium and ensure its
availability to tissues in amounts consistent with their needs.
Intestinal absorption of selenium is not regulated; the selenium
content of the body is regulated by hepatic production ofmeth-
ylated selenium compounds that are excreted predominantly in
the urine (2).
The major selenium transport form in plasma is Sepp1.3
Sepp1 in mice, rats, and humans consists of an N-terminal
domain with one selenocysteine residue in a thioredoxin-like
motif and a smaller C-terminal domain containing nine seleno-
cysteine residues (3). A short Sepp1 isoform, consisting only of
theN-terminal domain, has been identified (but not quantified)
in rat plasma along with longer isoforms that contain up to the
full 10 selenocysteine residues (4). Tissues take up “long iso-
form” Sepp1 from plasma via apoER2-mediated endocytosis
and utilize its selenium for synthesis of selenoproteins (5, 6).
Outside the blood circulation, kidney proximal convoluted
tubule cells take up fragments of Sepp1 from the urinary filtrate
via megalin-mediated endocytosis and use the selenium for
the synthesis of Gpx3, an extracellular glutathione peroxidase
(7, 8).
The liver is themain source of plasma Sepp1 (9, 10), although
lesser amounts of Sepp1 mRNA are present in many other tis-
sues, indicating that Sepp1 is widely expressed (11). Deletion of
Sepp1 in the mouse has severe consequences; brain and testis
become selenium-deficient and neurological dysfunction
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occurs unless a high selenium diet is fed (12, 13). Deletion of
Sepp1 also increases urinary selenium excretion, causing a
decrease in whole-body selenium (14).
Wepostulated that Sepp1 synthesis and excretorymetabolite
synthesis compete for selenium in the liver and therefore that
deletion of Sepp1makes more selenium available for excretion
(14). Such a loss of selenium in the urine might be expected to
lead to inability to conserve the element under conditions of
selenium deficiency. We were unable to study Sepp1/ mice
fed selenium-deficient diet, however, because feeding that diet
leads to neurological dysfunction and death within weeks (15).
To test our hypothesis that Sepp1 synthesis in the liver pre-
vents selenium deficiency by reducing its excretion, we pro-
duced mice with Sepp1 deleted only in hepatocytes. We rea-
soned that it might be possible to feed those mice selenium-
deficient diet without provoking neurological injury. That
would allow us to study seleniummetabolism under deficiency
conditions and to determine whether production of Sepp1 in
the liver protects against selenium deficiency. The experiments
reported here indicate that loss of hepatocyte Sepp1 synthesis
has widespread effects on systemic selenium metabolism and
worsens dietary selenium deficiency.
MATERIALS ANDMETHODS
Reagents—The reagents used for construction of the target-
ing vector for production of mice with a conditional allele of
Sepp1 were described previously (16). Oligonucleotides were
obtained from core lab facilities at the University of Utah and
Vanderbilt University Medical Center (Enzyme Reagents Core
Lab). 75Se-Selenite (specific activity 250 Ci/g selenium) was
purchased from the University of Missouri Research Reactor
Facility, Columbia, MO. NADPH was purchased from United
States Biochemical Corp. (Cleveland, OH). Glutathione reduc-
tase was purchased from Sigma. Digoxigenin-labeled nucleo-
tides and alkaline phosphatase-conjugated anti-digoxigenin
antibody were purchased from Roche Diagnostics. pCR4 Topo
plasmid and OneShot Top 10 cells were purchased from Invit-
rogen. High capacity cDNA reverse transcriptase kit and Power
SYBR Green PCR master mix were purchased from Applied
Biosystems. RNeasy mini kits were purchased fromQiagen. All
other chemicals were of reagent grade.
Construction of Targeting Vector—Toconstruct the targeting
vector, we followed a method described previously (16). The
construction process is summarized in Fig. 1. We first used
recombineering to subclone a 13.1-kb genomic fragment (Fig.
1A) from a BAC clone RP23-41H17, which had been obtained
fromBACPAC resources. The twooligonucleotides used in this
step (WS785 and WS786) are shown in Table 1. The resulting
plasmid from this step was named pStartK-Sepp1.
We inserted the 5 loxP site into the BglI site before the sec-
ond exon. The 3 loxP site and an FRT-flanked neo selection
cassette were inserted into the SpeI site located 3 of the Sepp1
coding sequence (Fig. 1B). The resulting plasmid was named
pStartK-Sepp1cond. To add a negative selection HSV-tk gene,
Gateway recombination was performed to quickly transfer the
modified Sepp1 genomic DNA into an HSV-tk containing vec-
tor named pWSTK2. The resulting targeting vector was named
pWSTK2-Sepp1cond.
Generation of Conditional Allele of Sepp1 inMice—Standard
electroporation of the linearized targeting vector into embry-
onic stem cells was performed as described (16). Long range
PCR and Southern blot analyses were performed to identify
correctly targeted embryonic stem cell clones. The 5 Southern
probe template (476 bp) was amplified by PCR from the BAC
clone RP23-41H17 with primers WS869-5F and WS870-5R
(Table 1). DNA isolated from embryonic stem cells was
digested with XbaI and run on a 0.9% agarose gel. Southern blot
was done with the 5 probe. The wild-type band was 9.6 kb, and
the targetedmutant band was 6.5 kb. Targeted embryonic stem
FIGURE1.Generationofa conditional knock-outmouse line forSepp1.Togenerate a conditional knock-out allele for Sepp1, a genomic fragment (boldblack
line) containing sequence from 5-CTGAAGCAACAGCTAAAAGA-3 to 5-AACACTCCATGCAAACTACA-3 of the Sepp1 gene was used for constructing the
targeting vector.A,genomic structure of thewild-type (WT) Sepp1gene,with its five exons shown in gray. The coding exons are gray andoutlined in black. The
second exon contains the start codon ATG. Sepp1 has 10 selenocysteines, each encoded by UGA in the mRNA. The first in-frame TGA is in the second exon.
The remainingnine in-frameTGAcodons are in exon5. The3UTRof exon5,where the two selenocysteine insertion sequence elements are located, isgray and
is not outlined inblack. B, loxP sites are representedby theopen arrowheads in the targeting vector. The 5 loxP sitewas inserted into the BglI site between exon
1 and exon 2. The 3 loxP site and an FRT-flanked neo selection cassette were inserted into the SpeI site after exon 5. The arrows show the location of primers
WS1004 and WS1005 used to assess the presence of the conditional allele. C, mating a heterozygous mouse with an Flp deleter mouse will delete the neo
sequence between the two FRT sites (represented by the open hexagon), resulting in a clean Sepp1 conditional allele.
Hepatic Selenoprotein P and SeleniumHomeostasis
NOVEMBER 23, 2012•VOLUME 287•NUMBER 48 JOURNAL OF BIOLOGICAL CHEMISTRY 40415
 at UNIV O










cells were injected into blastocysts using a standard protocol.
Male chimeric mice were bred with C57BL/6 females to obtain
the desired Sepp1c allele. The FRT-flanked neo selection cas-
sette can be deleted by crossing with a mouse line that ubiqui-
tously expresses the Flp recombinase or it may undergo self-
excision (Fig. 1C). The University of Utah Institutional Animal
Care and Use Committee approved animal protocols used to
generate the knock-out mouse.
Animal Husbandry—Adult Sepp1c/ mice (mice heterozy-
gous for the Sepp1 conditional allele) were transferred to the
animal facility at Vanderbilt University without having been
mated with Flp deleter mice. The mice were housed in plastic
cages with aspen shavings or alpha-dri bedding material. The
light/dark cycle was 12:12 h.Mice received pelleted diet and tap
water ad libitum. Experimental diets were formulated by Har-
lan-Teklad (Madison, WI) to our specifications (15). The diets
were Torula yeast-based and contained supplemental amounts
of selenium as sodium selenite. The basal (selenium-deficient)
form of this experimental diet was assayed, and it contained
0.006 0.003 mg of selenium/kg (n 7). Sodium selenite was
added to this diet during mixing to give final added selenium
concentrations of 0.25 mg/kg (control diet) and 0.15, 1, or 4
mg/kg. The Vanderbilt University Institutional Animal Care
andUseCommittee approved animal protocols for studies con-
ducted at Vanderbilt.
Pups from heterozygote matings were weaned 21 days after
birth and separated by sex. All mice used in experiments
reported hereweremales. The genotypes of all pupswere deter-
mined by PCR of genomicDNA isolated from ear notches. PCR
amplification with WS1004 and WS1005 (Table 1) identified
mice that were homozygous for the floxed gene. Pups from
these matings were used to establish the Sepp1c/c colony.
Deletion of Hepatic Sepp1—Sepp1c/c mice were mated with
albumin-cre recombinase mice (JAX strain B6.Cg-Tg(Alb-
cre)21Mgn/J that is congenic with C57BL/6 mice; stock num-
ber 003574). The resulting pups were heterozygous for the con-
ditional Sepp1 allele and were genotyped to identify pups
carrying the albumin-cre recombinase transgene. Sepp1c/
male and female mice that carried the albumin-cre transgene
were mated to produce Sepp1c/cmice carrying the albumin-cre
transgene (Sepp1c/c/alb-cre/). After this initial mating, it was
verified by PCR amplification of genomic DNA that a majority
of the progeny no longer carried the FRT-flanked neo cassette.
PCR amplification using oligonucleotides WS1006 and
WS1007 gave a 352-bp product indicating that the neo cassette
was absent. Male (Sepp1c/c) and female (Sepp1c/c/alb-cre/)
mice that did not carry the FRT-flanked neo cassette were used
as breeders to establish the colony. Male mice lacking hepatic
Sepp1 (Sepp1c/c/alb-cre/ mice) were identified by PCR and
selected for experiments.
Whole-body and Tissue Selenium Determination Experi-
ments—At weaning, Sepp1c/c and Sepp1c/c/alb-cre/ male
mice were fed control diet supplemented with 0.25 mg of sele-
nium/kg. Four weeks after weaning, mice were anesthetized
with isoflurane, and blood was removed from the inferior vena
cava with a syringe and needle. Blood was treated with diso-
dium EDTA (1 mg/ml) to prevent coagulation. An aliquot of
whole bloodwas taken for selenium assay, and the remainder of
the bloodwas centrifuged. Plasmawas frozen for assay to deter-
mine selenium biomarkers. Liver, kidney, muscle, testis, and
brain were harvested and frozen immediately in liquid nitro-
gen. The carcass was frozen in liquid nitrogen. Plasma, tissues,
and carcasses were stored at 80 °C. Whole-body selenium
concentration was calculated as the sum of blood, tissue, and
carcass selenium contents divided by body weight.
To assess the effect of seleniumdeficiency on tissue selenium
concentrations, weanling male Sepp1c/c and Sepp1c/c/alb-
cre/ mice were fed a basal (selenium-deficient) diet. They
were observed daily and weighed bi-weekly. After 12 weeks, the
micewere anesthetizedwith isoflurane, and bloodwas removed
from the inferior vena cava. Blood, tissues, and carcasses were
analyzed as in the group fed the 0.25 mg of selenium/kg diet.
To assess the selenium content of the liver in the form of
Gpx1, Gpx1/ and Gpx1/ weanling mice congenic with
C57BL/6 mice (17) were fed a diet supplemented with 0.25 mg
of selenium/kg for 4 weeks and then exsanguinated via the infe-
rior vena cava under isoflurane anesthesia. Tissues, blood, and
carcasses were taken for selenium analysis.
Biochemical Measurements—Selenium was measured using
amodification of the fluorometric assay of Koh andBenson (18)
and Sheehan and Gao (19). The ELISA used to measure plasma
Sepp1 detects the N-terminal domain of the protein, providing
ameasurement of the sum of all isoforms (20). Gpx activity was
determined using the coupled method with 0.25 mM hydrogen
peroxide as substrate (21).
TABLE 1
Targeting vector and other primers
Primer
designation primer sequence (53 3)
pStartK WS785 GTAGTGCTACTTATAAATCCCAACAGAGTCTCTTTTAGCTGTTGCTTCAGCGACTGAATTGGTTCCTTTAAAGCC
WS786 ATGTTTATTGCTCACCTAGGCATTATACTAAACACTCCATGCAAACTACAGCCGCACTCGAGATATCTAGACCCA
Southern blot probe WS869–5F GAGATCCCAGTAGGTAGGCGACTTG
WS870–5R CCTGTAACCTTGAGCCAAACTTCCT
PCR genotyping WS1004 TCCTAGATTGGCAGAGGATAGAATGAA
WS1005 TCAGAAACACCTTCCAACTGTAATGC
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75Se Labeling of Mouse Plasma—Sepp1c/c/alb-cre/ and
Sepp1c/c mice fed 0.25 mg of selenium/kg diet were injected
intraperitoneally with 10Ci of [75Se]selenite (in 0.15 MNaCl).
Four hours after 75Se administration, the mice were anesthe-
tized. Blood was obtained from the inferior vena cava and
treated with disodium EDTA to prevent coagulation. Plasma
was separated by centrifugation. Plasma (1l) was subjected to
SDS-PAGE on a 12.5% acrylamide gel. After staining with Coo-
massie Blue, the gel was dried and exposed to Kodak XAR film.
Metabolism of 75Se after Gavage of 75Se-Labeled Selenite—
Sepp1c/c/alb-cre/ and Sepp1c/c mice were gavaged with 10
Ci of 75Se-labeled selenite in 0.15 M NaCl. They were individ-
ually housed in metabolic cages. After 24 h, the mice were
removed from the cages, and urine and feces were collected.
The mice were anesthetized and exsanguinated by removal of
blood from the inferior vena cava. The liver was removed. 75Se
was determined in urine and liver using a -counter (Perkin-
Elmer Life Sciences model 1480 Wizard 3 gamma counter,
Shelton, CT).
Collection of Spermatozoa—The cauda of each epididymis
was minced in PBS. An aliquot of the sperm suspension was
added to 4% formaldehyde in 0.1 M phosphate buffer, pH 7.6.
Sperm counts were performed in a hemocytometer. When the
spermatozoa were counted, each was noted to be either normal
or kinked at the midpiece-principal piece junction.
In SituHybridization—Nonisotopic in situ hybridizationwas
performed as described previously (6) using digoxigenin-la-
beled sense and antisense Sepp1 riboprobes and formaldehyde-
fixed cryosections ofmouse liver. A 641-bpmSEPP1 cDNAwas
prepared by PCR using MB23A1 plasmid (12) and primers 5-
AGCCAGCTGATACTTGTGTCTTCTGCAGGCAT-3 and
5-AAAGGTGCAAGCCTTCACTTGCTGTGGTGT-3. The
PCR product was gel-purified and ligated into the pCR4 Topo
plasmid. Following transformation into OneShot Top10 cells,
individual clones were analyzed by PCR to identify the orienta-
tion of the mSEPP1 cDNA insert. Clones with opposite insert
orientation were used to prepare template DNA by PCR, which
included the plasmid T7 promoter and the mSepp1 insert. The
purified PCR products were used in transcription reactions to
prepare sense and antisense digoxigenin-labeled riboprobes as
described previously (6).
RT-PCR—Frozen tissuewas pulverized under liquid nitrogen
and then treated with TRIzol reagent. Total RNA was isolated
according to the manufacturer’s protocol. RNA was further
purified on an RNeasy mini column following the manufactur-
er’s instructions. RNA concentration was determined by mea-
surement of A260. cDNA was prepared using high capacity
cDNA reverse transcriptase kit following the manufacturer’s
instructions. 100 ng of total RNA was used per 20 l of cDNA
synthesis reaction. Quantitative PCR for gene expression was
performed using Power SYBRGreen PCRmaster mix with 1l
of cDNA in a total reaction volume of 20 l. Gene-specific
primers were used at a final concentration of 250 nM. StepOne-
Plus RT-PCR system and StepOne software Version 2.1
(Applied Biosystems) were used to collect and analyze data.
Three replicates of each sample were amplified. Relative quan-
titation of RNA levels was determined by comparativeCT reac-
tions (CT analysis). Primers used for amplification of Sepp1,
Gpx1, and hypoxanthine-guanine phosphoribosyltransferase
are listed in Table 1. Hypoxanthine-guanine phosphoribosyl-
transferase served as the endogenous control. The target
mRNA quantity in each tissue was expressed in arbitrary units
(relative quantitation).
Statistics—Statistical comparisons between groups were
made on an iMac using Prism 4 for Macintosh Version 4.0c
software program (GraphPad Software, Inc.). Tukey’s Multiple
ComparisonTest was applied after analysis by one-way analysis
of variance. Where appropriate, Student’s t test was used to
compare groups. These groups were considered to be signifi-
cantly different with p	 0.05.
RESULTS
TheHepatocyte Is the Predominant, butNot Exclusive, Source
of PlasmaSepp1—Fig. 2 demonstrates that liver has the greatest
relative amount of Sepp1 mRNA of the tissues we examined in
Sepp1c/cmice. Kidney ranked secondwith 38% of the liver level.
Skeletal muscle, heart, and testis followed with 10, 6, and 6%,
respectively. Sepp1 mRNA was present in whole brain, but at
less than 2% of the liver level. These results confirm a report by
others that Sepp1 is expressed in many tissues (11).
Sepp1c/c mice were bred with alb-cre/ mice to produce
Sepp1c/c/alb-cre/ mice that had Sepp1 deleted in hepato-
cytes. Liver Sepp1 mRNA fell to 2% in those mice, but Sepp1
mRNA did not change significantly in the other tissues tested
(Fig. 2). Those results are consistent with Sepp1c/c/alb-cre/
mice having Sepp1 deleted in hepatocytes but not in nonhepa-
tocyte liver cells or in extra-hepatic tissues.
Several populations of hepatocytes are present in the liver.
Peri-portal hepatocytes are the first to encounter blood from
the portal vein and thus receive greater amounts of oxygen and
absorbed nutrients than do peri-central hepatocytes. In situ
hybridization revealed a strikingly zonal distribution of Sepp1
mRNA in liver with high staining in the peri-portal zone and
low to undetectable staining in the peri-central zone (Fig. 3A).
No stainingwas detectable in liver froma Sepp1/mouse (Fig.
3B).
Selective deletion of Sepp1 in hepatocytes lowered plasma
Sepp1 concentration in mice fed a selenium-adequate diet
(supplemented with 0.25 mg of selenium/kg) to 4% of the value
in Sepp1c/c mice fed the same diet (Fig. 4A). The dietary sele-
FIGURE 2. Expression of Sepp1 mRNA in tissues frommice with deletion
of hepatocyte Sepp1 (Sepp1c/c/alb-cre/ mice) and in floxed (Sepp1c/c)
controls. Values are means with 1 S.D. indicated by a bracket, n 3–4. The
effect of gene deletion was assessed in each tissue by Student’s t test. The
only significant difference (p	 0.05) was in liver, in which the deleted value
was 2% of the control. RQ, relative quantitation.
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nium concentration that is needed to maximize selenoprotein
levels in wild-type mice is 0.10–0.15 mg/kg (22). In a separate
experiment (Fig. 4B), increasing dietary selenium supplemen-
tation from 0.25 to 1 mg/kg produced a small, but significant,
rise in plasma Sepp1 from 4% of the Sepp1c/c value in the exper-
iment depicted in Fig. 4A to 10% of it, indicating that selenium
supply to some nonhepatocyte Sepp1-producing tissues was
not adequate in Sepp1c/c/alb-cre/ mice fed the diet supple-
mented with 0.25 mg of selenium/kg. An additional increase in
dietary selenium supplementation to 4 mg/kg did not raise
FIGURE 3. In situ hybridization showing Sepp1mRNA (dark stain) in mouse liver. Portal veins are indicated by filled squares and central veins by asterisks.
Mice had been fed a diet supplemented with 0.25 mg of selenium/kg. A depicts liver from a C57BL/6 mouse and B depicts liver from a congenic Sepp1/
mouse.
FIGURE 4. Effect of dietary selenium on plasma selenium biomarkers in Sepp1c/c/alb-cre/mice. A depicts plasma selenium biomarkers in Sepp1c/c/alb-
cre/ (n5) andSepp1c/c (n4)mice thathadbeen fedadiet supplementedwith0.25mgof selenium/kg for 4weeksbeginningatweaning.Bdepictsplasma
seleniumbiomarkers inmice feddiets supplementedwith 0.25, 1, and 4mgof selenium/kg. In that experiment,mice that hadbeen fed 0.25mgof selenium/kg
diet for 1–2months beginning at weaningwere used for the study. One group (n 4) continued to be fed the same diet, and two other groups (n 5 in each
group) were switched to the 1 and 4mg/kg diets for 4 weeks before plasma was obtained. Values in both panels are means with 1 S.D. indicated by a bracket.
Percentages in A indicate that values were significantly different (p 	 0.05) by Student’s t test. Asterisks in B indicate that values were different from the
preceding value (p	 0.05) by Tukey’s multiple comparison test.
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plasma Sepp1 concentration further. These findings indicate
that nonhepatocyte sources supply
10% of plasma Sepp1 and
imply that hepatocyte-produced Sepp1 provides selenium to
other tissues that are also sources of plasma Sepp1.
The plasma Gpx activity in Sepp1c/c/alb-cre/mice fed the
diet supplemented with 0.25 mg of selenium/kg was very low
(Fig. 4A). Increasing dietary selenium supplementation to 1
mg/kg and then to 4mg/kg raised plasma Gpx activity progres-
sively (Fig. 4B). These results strongly suggest that non-Sepp1
selenium forms, likely of low molecular weight, can replace
Sepp1 as a source of selenium for Gpx3 synthesis when sele-
nium intake is high. Plasma selenium concentrations in
Sepp1c/c/alb-cre/ mice fed different amounts of selenium
reflected the levels of the two selenoproteins (Fig. 4B).
The presence of plasma selenoproteins was further evaluated
using autoradiography of an SDS-polyacrylamide gel (Fig. 5).
The Sepp1c/c lane contained two 75Se bands as has been
observed in wild-type mice (23). The darker band at 50 kDa
represents Sepp1, and the lighter one at 23 kDa represents
Gpx3. A 50-kDa 75Se band was present in the Sepp1c/c/alb-
cre/ lane in Fig. 5, consistent with Sepp1 being present in
Sepp1c/c/alb-cre/ mouse plasma. The migrations of Sepp1
and Gpx3 were similar in Sepp1c/c and Sepp1c/c/alb-cre/
plasma, although the relative amounts of 75Se in the bandswere
reversed. Thus, Sepp1 is present in plasma from Sepp1c/c/alb-
cre/mice, although at a concentration of 10% or less that in
Sepp1c/c mice (Fig. 4).
Hepatocyte Sepp1 Synthesis Promotes SeleniumRetention in the
Body and Transfer from the Liver to Extra-hepatic Tissues—
Deletion of Sepp1 in the whole mouse increases urinary sele-
nium excretion, thereby decreasing whole-body selenium (14).
To explain these findings, we hypothesized that synthesis of
Sepp1 competes for metabolically available selenium in hepa-
tocytes with synthesis of excretory seleniummetabolites. Thus,
deleting hepatocyte Sepp1 should make more selenium avail-
able for the excretory pathway. We tested this hypothesis by
comparing selenium metabolism in Sepp1c/c/alb-cre/ and
Sepp1c/c mice.
An experiment was designed to determine the fate of newly
administered, and thus metabolically available, selenium. Mice
fed a selenium-adequate diet (supplemented with 0.15 mg of
selenium/kg) received 75Se-labeled selenite by gavage to trace
metabolically available selenium. Urine was collected for 24 h,
and then themicewere sacrificed. Fig. 6A shows that deletion of
hepatocyte Sepp1 more than doubled 75Se excretion in urine.
Liver 75Se was 25% higher in the mice with deletion of Sepp1
than in their controls, likely reflecting increased incorporation
of metabolically available selenium into liver selenoproteins
(see Scheme 1). These results are consistent with there being
competition for 75Se between synthesis of Sepp1 and synthesis
of excretory metabolites. In addition, they suggest that there is
competition for metabolically available selenium between
synthesis of Sepp1 and synthesis of liver intracellular
selenoproteins.
FIGURE 5. Effect of hepatocyte Sepp1 deletion on the presence of plasma
selenoproteins. Mice fed the diet supplemented with 0.25 mg of seleni-
um/kg were injected intraperitoneally with 10 Ci of 75Se-labeled selenite,
and plasmawas obtained 4 h later. After SDS-PAGE had been performed, the
gel was dried and used for autoradiography. Migrations of protein standards
are indicated to the left. Sepp1 migrates at 50 kDa and Gpx3 migrates at 23
kDa (25).
FIGURE 6. Effect of hepatocyte Sepp1 deletion on urinary excretion and
liver incorporation of gavaged 75Se administered as 75Se-labeled sele-
nite. A shows results inmice fed a diet supplementedwith 0.15mg of seleni-
um/kg for 5 weeks beginning at weaning, and B shows results in mice fed a
selenium-deficient diet for 20weeks beginning atweaning. Values aremeans
with 1 S.D. indicated by the bracket, n  4–6. Percentage differences are
given for pairs of values that were significantly different from each other by
Student’s t test (p	 0.05).
SCHEME 1.Proposed fate ofmetabolically available selenium (‘Se’) in the
hepatocyte.Hepatocytes have several sources of selenium that are immedi-
ately available for further metabolism. Synthesis of sec-tRNA[ser]sec ➀ com-
petes for selenium with methylation reactions ➁ that produce excretory
metabolites. Synthesis of Sepp1 ➂ for export to the plasma competes for
sec-tRNA[ser]sec with synthesis of intracellular selenoproteins➃. Liver seleno-
proteins turn over ➄ to release selenium. The asterisks on steps ➀ and ➂
indicate the path of selenium favored under conditions of selenium
deficiency.
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When the same experiment was carried out in selenium-
deficient mice, the results were somewhat different (Fig. 6B).
Urinary 75Se excretion was very low and not significantly dif-
ferent between mouse groups. These findings are consistent
with synthesis of sec-tRNA[ser]sec out-competing synthesis of
excretory metabolites for metabolically available selenium
under selenium-deficient conditions, even when Sepp1 has
been deleted. Liver 75Se was sharply higher in the mice with
Sepp1 deleted, likely caused by diversion of sec-tRNA[ser]sec
from synthesis of Sepp1 to synthesis of intracellular selenopro-
teins (Scheme 1). These results indicate that the pathways to
synthesis of selenoproteins (sec-tRNA[ser]sec) and to excretory
metabolites compete formetabolically available selenium in the
hepatocyte and that synthesis of Sepp1 competeswith synthesis
of other selenoproteins for sec-tRNA[ser]sec.
Gpx1 contains 53% of liver selenium in selenium-replete
C57BL/6 mice (Fig. 7A), and its synthesis would therefore be
expected to utilize a large fraction of the sec-tRNA[ser]sec pro-
duced in that organ. Because synthesis of Gpx1 would compete
for sec-tRNA[ser]sec with synthesis of Sepp1, we assessed
expression of their mRNAs under selenium-adequate and sele-
nium-deficient conditions in C57BL/6mice. In confirmation of
earlier reports (22), selenium-deficient liver Gpx1 mRNA was
only 15% of that in selenium-replete controls, whereas Sepp1
mRNA only fell to 61% under the same conditions (Fig. 7B).
These results suggest that utilization of selenium is shifted from
synthesis of Gpx1 to synthesis of Sepp1 under selenium-defi-
cient conditions, enhancing the supply of selenium to extra-
hepatic tissues when the element is in short supply.
The effect of hepatocyte Sepp1 deletion on tissue selenium
concentrations was determined. Deletion of Sepp1 in hepato-
cytes decreased whole-body selenium concentration to 58% of
the Sepp1c/c value inmice fed our usual selenium-adequate diet
supplementedwith 0.25mgof selenium/kg (Fig. 8A), consistent
with increased urinary excretion ofmetabolically available sele-
nium (Fig. 6A). In accord with the decrease in whole-body sele-
nium, its concentrations in tissues were also decreased in
Sepp1c/c/alb-cre/ mice, but to varying degrees. Liver main-
tained its selenium better than other tissues, probably because
deletion of Sepp1 allowed liver intracellular selenoproteins a
greater supply of sec-tRNA[ser]sec (Scheme 1). Brain and testis
retained selenium better than kidney and muscle, presumably
because they have higher expressions of apoER2, which is
responsible for endocytosis of plasma Sepp1 (5).
Under conditions of selenium deficiency, deletion of hepato-
cyte Sepp1 lowered whole-body and tissue selenium except for
that in liver, which was sharply higher than liver selenium in
Sepp1c/c mice (Fig. 8B). Strikingly, the liver contained 53% of
whole-body selenium in selenium-deficient Sepp1c/c/alb-
cre/mice but only 8% of whole-body selenium in selenium-
deficient Sepp1c/c mice. Thus, most of the selenium not
secreted as Sepp1 in these mice was retained in hepatocyte sel-
enoproteins. These results demonstrate the importance of
Sepp1 secretion by the liver in supplying extra-hepatic tissues
with selenium and maintaining the metabolic relationships
outlined in Scheme 1.
Deletion of Hepatocyte Sepp1 Synthesis Worsens Clinical
Signs ofDietary SeleniumDeficiency—Because incorporation of
metabolically available hepatocyte selenium into Sepp1 is a
mechanism for retaining selenium in the body and for distrib-
uting it to extra-hepatic tissues (Figs. 6 and 8), deletion of hep-
atocyte Sepp1 would be expected to exacerbate the signs of
dietary selenium deficiency. To evaluate this possibility,
Sepp1c/c/alb-cre/ mice and control Sepp1c/c mice were fed
selenium-deficient diet beginning at weaning. Both groups
gained weight for 12 weeks, at which time Sepp1c/c/alb-cre/
mice ceased gaining weight, although Sepp1c/c mice continued
to gain (Fig. 9).
FIGURE 7. Comparison of Gpx1 and Sepp1 in the liver. A depicts liver and
whole-body selenium concentrations of Gpx1/ and Gpx1/ mice fed a
diet supplemented with 0.25 mg of selenium/kg for 4 weeks beginning at
weaning. B depicts relative Gpx1 and Sepp1 mRNA in livers of mice fed sele-
nium-deficient or selenium-adequate (0.25 mg of selenium/kg) diets for 16
weeks beginning at weaning. Values are means with 1 S.D. indicated by a
bracket (n  5). All pairs were significantly different by Student’s t test (p 	
0.05).
FIGURE 8. Effect of hepatocyte Sepp1 deletion on tissue andwhole-body
selenium concentrations in selenium-adequate (A) and selenium-defi-
cient (B) mice. Selenium-adequate mice were fed a diet supplemented with
0.25 mg of selenium/kg for 4 weeks beginning at weaning. Selenium-defi-
cient mice were fed a selenium-deficient diet for 12 weeks beginning at
weaning. Values aremeanswith thebracket indicating1S.D. (n3–4). Values
in every pair were significantly different from each other (p 	 0.05) by Stu-
dent’s t test. Percentages indicate thedifferences. Plasmabiomarker valuesof
the selenium-adequate animals (A) are shown in Fig. 4A. Plasma Sepp1 was
not detectable (	0.5 mg/liter) in any of the four selenium-deficient Sepp1c/c/
alb-cre/mice (B) and was 2.2 0.1 mg/liter, n 3, in the Sepp1c/c mice.
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Selenium deficiency causes azoospermia and structural
abnormalities of spermatozoa (24). The sperm count in the epi-
didymal cauda of Sepp1c/c/alb-cre/ mice fed selenium-defi-
cient diet for 24 weeks was 39% of that in C57BL/6mice fed the
same diet (Table 2). Spermatozoa of selenium-deficient mice
become “kinked” at the junction of the mid-piece and principal
piece (25). Nearly all the spermatozoa of the selenium-deficient
Sepp1c/c/alb-cre/ mice were kinked in this manner, and
many fewer of the spermatozoa of the control mice were so
kinked (Fig 10 and Table 2).
The brain is better protected against selenium deficiency
than any other tissue (26). However, in Sepp1c/c/alb-cre/
mice fed a selenium-deficient diet for 12 weeks, brain selenium
concentration fell to 37 7 ng/g (n 4), 48% of the concentra-
tion in control Sepp1c/c mice fed the same diet, and 29% of
Sepp1c/c mice fed the selenium-adequate diet supplemented
with 0.25 mg selenium/kg (Fig. 8B). Thus, deletion of hepato-
cyte Sepp1 reduced the ability of the brain to maintain its sele-
nium in selenium deficiency.
Beginning 16 weeks after weaning, the Sepp1c/c/alb-cre/
mice fed selenium-deficient diet began to curl their hind limbs
when lifted by the tail (Fig 11A). This finding was described by
others in wild-type mice only after they had been fed selenium-
deficient diet through three generations (27). In addition, the
mice developed wide-based gait in their hind limbs (Fig 11B)
beginning 22 weeks after weaning. The hind limbs remained
impaired until the observation period was terminated at 80
weeks, but this disability did not worsen significantly and the
front limbs remained unaffected. The Sepp1c/c/alb-cre/mice
fed a selenium-deficient diet for 80 weeks were still able to
move about; they did not develop the severe neurological dys-
function observed in Sepp1/ mice fed a selenium-deficient
diet for only 2 weeks (12). Thus, in addition to decreasing the
selenium concentration in all tissues except liver, deletion of
hepatocyte Sepp1 worsened the clinical signs of selenium defi-
ciency in mice fed a selenium-deficient diet.
DISCUSSION
The results presented here demonstrate that 90% of plasma
Sepp1 originates in hepatocytes and that deletion of hepatocyte
FIGURE 9. Body weights of Sepp1c/c/alb-cre/ (n  8) and Sepp1c/c (n 
12)mice fed a selenium-deficient diet for 22weeks beginning at week 0
(weaning).Values aremeanswith1S.D. indicatedbyabracket. Thehorizontal
line is above theportionof theweight curves inwhich thepairs of valuesdiffer
by Student’s t test (p	 0.05).
TABLE 2
Sperm counts andmorphology in Sepp1c/c/Alb-cre/mice fed a sele-






5 17 6.7b 43 8.3b
Percentage of spermatozoa
with kinks
5 95 2.5c 37 5.5c
a Values are means 1 S.D.
b,c Values with the same superscript are different (p	 0.05) by Student’s t test.
FIGURE 10. Effect of feeding selenium-deficient diet for 24 weeks on the
morphology of spermatozoa in the cauda epididymis from C57BL/6
(A) and Sepp1c/c/alb-cre/ (B) mice. Arrows indicate kinks in spermatozoa
at the junction of the midpiece and the principal piece.
FIGURE 11. Selenium deficiency affects hind limbs and gait of Sepp1c/c/
alb-cre/mice.Micewere fed a selenium-deficient diet for 61weeks begin-
ning at weaning. A shows curling of hind limbs when the mouse was picked
up by the tail. B shows splaying of hind limbs but not fore limbs.
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Sepp1 leads to major changes in whole-body seleniummetabo-
lism. Those changes in metabolism impair selenium supply to
extra-hepatic tissues and worsen dietary selenium deficiency.
The liver is well suited to regulate whole-body selenium
metabolism because it has a greater supply of the element than
do other tissues. Portal vein blood transports absorbed sele-
nium directly to the liver in small molecule form (9). Selenome-
thionine, the major dietary form of selenium, is catabolized in
the liver (28, 29), freeing its selenium for further metabolism in
the hepatocyte.
Fig. 6 indicates that the liver apportions this rich supply of
selenium between selenoprotein synthesis and synthesis of
excretory metabolites. This regulation likely occurs at the bio-
chemical level of selenide, the product of selenocysteine catabo-
lism by selenocysteine lyase (28). Selenide can be metabolized to
selenophosphate, an immediate precursor of sec-tRNA[ser]sec, by
selenophosphate synthetase (30) or it can bemethylated to pro-
duce excretory metabolites (2, 31).
An early study in rats demonstrated a selenium intake
threshold of 0.054 mg of selenium/kg diet below which urinary
excretion of metabolically available selenium did not respond
to changes in dietary selenium intake (32). However, tissue dis-
tribution of selenium and selenoprotein synthesis both
responded to dietary selenium levels below that threshold (32,
33). Thus, Fig. 6B and these earlier reports suggest that meta-
bolically available selenium is directed primarily to synthesis of
sec-tRNA[ser]sec at very low selenium intakes, and only when
intake rises above a “threshold” is selenium also used for the
production of excretory metabolites as well. The molecular
mechanism of this regulation is not known. However, it pro-
motes selenoprotein synthesis in the hepatocyte and thereby
protects the organism against selenium deficiency.
Once sec-tRNA[ser]sec has been produced in the liver, it is
used for synthesis of selenoproteins, either Sepp1 for export or
selenoproteins that remain in the hepatocyte (Scheme 1). Dele-
tion of Sepp1 in hepatocytes diverted administered 75Se to the
intracellular selenoproteins, especially under selenium-defi-
cient conditions (Fig. 6B). As a consequence of this diversion,
53% of whole-body selenium was retained in the livers of sele-
nium-deficient Sepp1c/c/alb-cre/ mice compared with only
8% in selenium-deficient Sepp1c/c mice that were able to syn-
thesize Sepp1 and thereby export hepatic selenium to other
tissues (Fig. 8B). These results demonstrate that the production
of Sepp1 by the liver is a mechanism for distributing selenium
to extra-hepatic tissues, especially under selenium-deficient
conditions.
A further mechanism for ensuring selenium supply to extra-
hepatic tissues is the down-regulation of hepatic Gpx1 mRNA
under selenium-deficient conditions. Gpx1 contains 53% of
hepatic selenium under selenium-adequate conditions (Fig.
7A). In selenium-deficient liver, Gpx1 mRNA fell sharply rela-
tive to Sepp1 mRNA (Fig. 7B). A detailed study of most of the
mouse liver selenoproteome has shown that in selenium defi-
ciency the mRNAs of three liver selenoproteins (including
Gpx1) fall sharply; five (including Sepp1) decrease moderately;
and nine remain unchanged (34). These changes in mRNA lev-
els presumably allow a greater amount of the metabolically
available selenium in liver to be incorporated into Sepp1 for
supply of the element to extra-hepatic tissues while maintain-
ing vital intracellular selenoproteins. Other mechanisms of dif-
ferentially regulating translation of selenoproteins are under
investigation, but no results have yet been presented that are rele-
vant to hepatic Sepp1 production (35). Thus, available results sug-
gest that supplyof seleniumby the liver toother tissues is regulated
at the levelof apportionmentof sec-tRNA[ser]sec betweensynthesis
of Sepp1 and synthesis of intracellular selenoproteins as well as at
the level of competition between selenium excretion and sec-
tRNA[ser]sec synthesis.
Sepp1 is not the only transport form of selenium. Sepp1/
mice are viable when fed a high selenium diet (12). The other
plasma selenoprotein, Gpx3, does not appear to transport sele-
nium for specific uptake by cells (5), and mice with both Sepp1
and Gpx3 deleted are viable (23). Thus, the non-Sepp1 trans-
port form appears to be a small molecule.
This small molecule form (or forms) of selenium has been
detected but not characterized (9, 36). When compared with
the Sepp1-apoER2 pathway, the small molecule pathway
appears to lack the ability to distinguish between high need
tissues and lowneed tissues.Moreover, to be effective, the small
molecule pathway requires amuch higher selenium intake than
does the Sepp1-apoER2 pathway (12). Thus, this second tier
pathway of selenium transport appears to be nonspecific and to
be less effective than the Sepp1-apoER2 pathway.
Until 10 years ago, selenium deficiency could only be pro-
duced by feeding selenium-deficient diet. The major clinical
sign of selenium deficiency in mice was male infertility caused
by abnormal spermatozoa (27). Only when fed a selenium-de-
ficient diet through three generations did mice develop a mild
neurological abnormality (27). Thus, wild-type mice tolerate
severe nutritional selenium deficiency with relatively mild clin-
ical impairment, aside from male infertility.
Ten years ago, Sepp1/ mice were produced and were
observed to have abnormal spermatozoa and severe neurolog-
ical injury leading to death when fed a diet considered to be
adequate in selenium forwild-typemice (12, 13). Feeding a high
selenium diet (1 mg of selenium/kg diet) to Sepp1/ mice
prevented overt neurological injury and allowed a long life span,
but it did not completely prevent neuropathological abnormal-
ities (37). Neither did it completely correct the sperm abnor-
malities (25). We interpret this to indicate that the small mole-
cule selenium could largely replace Sepp1 in supplying the
brain with selenium but that it did not meet the apparently
higher selenium demands of the testis.
Other groups have studied mice with selective deletion of
Trsp (the gene for tRNA[ser]sec) in hepatocytes (10, 38). Those
mice were unable to synthesize any selenoproteins in their
hepatocytes. Brain selenium concentration was not affected by
loss of hepatocyte selenoprotein synthesis. The plasma Sepp1
concentration was shown by Western blot to be sharply
decreased, but it was not quantified in those studies. This study
demonstrates that up to 10% of plasma Sepp1 is produced by
extra-hepatocyte tissues (Fig. 4). Severe selenium deficiency in
wild-type mice lowers plasma Sepp1 concentration to less than
10% without producing neurological signs (26). Thus, it is not
surprising that mice with deletion of Sepp1 or of Trsp in hepa-
tocytes that are fed selenium-adequate diet maintain their
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brain selenium (Fig. 8A) and do not develop neurological
abnormalities.
When fed a selenium-deficient diet, however, Sepp1c/c/alb-
cre/mice developed signs of selenium deficiency not seen in
selenium-deficient wild-type mice. In addition to developing
abnormal spermatozoa, they ceased gaining weight 12 weeks
post-weaning (Fig. 9) and began losing strength in their hind
limbs at 22 weeks (Fig 10). Plasma Sepp1 was undetectable
(	2% of Sepp1 in wild-type selenium-adequate mice) in
Sepp1c/c/alb-cre/ mice fed a selenium-deficient diet for 12
weeks, although it was detectable at 8% in Sepp1c/c mice under
the same conditions (Fig. 8 legend). The observation that clin-
ical signs did not worsen further after 22 weeks suggests the
establishment of a new selenium steady state at a very low
intake (dietary selenium concentration of 0.006 mg/kg). Thus,
mice with deletion of hepatic Sepp1 can be used as a model for
producing extremely severe dietary selenium deficiency in all
tissues with the exception of the liver.
Sepp1 is expressed within the brain by astrocytes and likely
by other cells (39, 40). The Sepp1 receptor apoER2 is present on
neurons (41), so it is possible that Sepp1 functions to maintain
appropriate distribution of selenium among cells in the brain as
it does among tissues in the body (Fig. 8). Supporting this pos-
sibility is the very low selenium concentration in the brains of
selenium-deficient Sepp1c/c/alb-cre/mice (37 ng/g) with no
overt neurological signs (Fig. 8B). Sepp1/ mice fed a seleni-
um-deficient diet for 1–2 weeks have essentially the same brain
selenium level but have severe neurological abnormalities.4
Thus, in mice with very low brain selenium concentrations,
Sepp1 expression in brain protects against brain injury. This
strongly suggests that Sepp1 produced in the brain provides
selenium to high need brain cells. However, it does not rule out
other, perhaps enzymatic, protective functions of Sepp1 in the
brain.
In conclusion, this study demonstrates that the process of
incorporating metabolically available selenium into Sepp1 in
the hepatocyte is central to seleniumhomeostasis in themouse.
As selenium supply becomes limited, alternative routes of its
hepatic metabolism (production of excretory metabolites and
of intracellular selenoproteins) diminish, allowing continued
Sepp1 synthesis for export into the plasma. The Sepp1 in
plasma provides selenium to extra-hepatic tissues via apoER2-
mediated endocytosis (5), thus protecting against selenium
deficiency in them.
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